Acura Pharmaceuticals (ACUR) Stock Analysis & Winston Score
Acura Pharmaceuticals is a small drug company that develops prescription medicines with built-in abuse-deterrent features. Its main technology, called Aversion, is designed to make certain pills harder to crush, dissolve, or misuse — targeting the prescription opioid abuse problem. The company's products are sold to patients through pharmacies, with healthcare providers and insurers as key decision-makers. Acura makes money by licensing its drug formulation technology to larger pharmaceutical companies and earning royalties on product sales, rather than manufacturing and selling drugs at large scale itself. It operates primarily in the United States and is a very small company, with a market cap near zero and ongoing operating losses. The biggest risk the business faces is commercial adoption — if larger partners do not actively promote products using Acura's technology, or if insurers do not cover them over cheaper generic alternatives, the company struggles to generate enough revenue to cover its costs.
Winston Score: 16/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (4/30)
- Growth: Weak (2/20)
- Cash Flow: Weak (0/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Mixed (6/15)
Key Facts
Price: $0.00
Market Cap: $0M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
